WO2008087030A1 - Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments - Google Patents

Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments Download PDF

Info

Publication number
WO2008087030A1
WO2008087030A1 PCT/EP2008/000343 EP2008000343W WO2008087030A1 WO 2008087030 A1 WO2008087030 A1 WO 2008087030A1 EP 2008000343 W EP2008000343 W EP 2008000343W WO 2008087030 A1 WO2008087030 A1 WO 2008087030A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
substituted
branched
linear
Prior art date
Application number
PCT/EP2008/000343
Other languages
French (fr)
Inventor
Antonio Torrens-Jover
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07000947A external-priority patent/EP1947088A1/en
Priority claimed from EP07384013A external-priority patent/EP1950203A1/en
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Priority to EP08707108A priority Critical patent/EP2114892A1/en
Priority to US12/523,451 priority patent/US20100069364A1/en
Publication of WO2008087030A1 publication Critical patent/WO2008087030A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.
  • lipid abnormalities are specifically defined as follows :
  • Raised plasma triglycerides > 1.7 mmol/L; 150 mg/dL.
  • NCEP National Cholesterol Education Programme
  • ATP ATP
  • Raised plasma triglycerides ( ⁇ 1.7 mmol/L; 150 mg/dL).
  • dislipidaemia also encompasses the following disorders as described by the NCEP in their ATP III Guidelines (NCEP ATP III, 2002): heterozygous familial hypercholesterolaemia (FH), homozygous familial hypercholesterolaemia (FH) 1 familial defective apolipoprotein B-100 (FDB), polygenic hypercholesterolaemia hypertriglyceridaemia including familial combined hyperlipidaemia, familial hypertriglyceridaemia and familial dysbetalipoproteinaemia, low HDL-cholesterol (with or without hypertriglyceridaemia), diabetic dyslipidaemia (ie atherogenic dyslipidaemia in persons with Type 2 diabetes), elevated LDL-cholesterol and atherogenic dyslipidaemia.
  • Other secondary dyslipidaemias include, but are not limited to, those evoked by hypothyroidism, nephrotic syndrome and other renal disorders, obstruct
  • the necessity to treat dyslipidaemia in patients is defined not only by the serum or plasma concentrations of individual lipids, but also by the coexistence of lipid abnormalities with other cardiovascular risk factors and/or related disorders, eg hypertension, cardiovascular disease and Type 2 diabetes, the patient's medical history, also whether or not the patient has a history of cerebrovascular or cardiovascular adverse events, eg myocardial infarction, congestive heart failure, angina and/or haemorrhagic or thromboembolic stroke.
  • cardiovascular risk factors and/or related disorders eg hypertension, cardiovascular disease and Type 2 diabetes
  • the patient's medical history also whether or not the patient has a history of cerebrovascular or cardiovascular adverse events, eg myocardial infarction, congestive heart failure, angina and/or haemorrhagic or thromboembolic stroke.
  • Such clinical factors are well known to those skilled in the art and are taken into account in the decision whether or not to prescribe medications to treat dyslipidaemia.
  • Dyslipaemia with or without obesity, is major cause of insulin resistance and a key driver of the progression of pre-diabetes (insulin resistance and/or impaired glucose tolerance) to Type 2 diabetes (Boden & Laakso, 2004; Bays et al, 2004; IDF, 2005). Furthermore, there is also a high degree of association between Type 2 diabetes and dyslipidaemia whereby the latter is characterised by raised plasma levels of small, dense LDL-cholesterol particles, elevated triglycerides and low concentrations of HDL-cholesterol particles (Boden & Laakso, 2004).
  • the Metabolic Syndrome consists of a cluster of cardio-metabolic risk factors, but obesity, central adiposity, lipid abnormalities, (raised serum triglycerides, low serum HDL-cholesterol) and impaired glucose tolerance or Type 2 diabetes are core symptoms of the Metabolic Syndrome, irrespective of whether a diagnosis of is made according to the criteria defined by the World Health Organization (WHO, 1999), the National Cholesterol Education Programme - Third Adult Treatment Panel (NCEP ATP III, 2001 ) or the International Diabetes Federation (IDF, 2005).
  • WHO World Health Organization
  • NCEP ATP III National Cholesterol Education Programme - Third Adult Treatment Panel
  • IDF International Diabetes Federation
  • ACAT Acyl CoA-Cholesterol Acyltransferase
  • statins which are as such quite potent lipid lowering agents acting by inhibitng HMG-CoA reductase and are useful for the prophylaxis and/or treatment of cardiovascular diseases
  • safety concern related to the use of statins is the development of rhabdomyolysis, the pathological breakdown of skeletal muscle, which may lead to acute renal failure when muscle breakdown products damage the kidney. Consequently, there is still a big demand for potent therapeutic agents to treat dyslipidaemia, possibly, showing less incidents of undesired side effects of statins, or at least less pronounced.
  • the present invention relates to a substituted pyrazoline compound of general formula I,
  • Z is Ci- 4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • Z' is selected from hydrogen; C 1-4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • X and Y independently represent an optionally at least monsubstituted mono- or polycyclic ring-system
  • FT represents OR" or NR B R a , with
  • R 8 representing a hydrogen atom or a branched or linear C ⁇ -alkyl group
  • R 8 representing a hydrogen atom or a branched or linear C 1-3 -alkyl group, while R 9 is representing an optionally at least monsubstituted mono- or polycyclic ring-system;
  • R 8 and R 9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical
  • Formula I is also covering the diastereoisomers and thus may also be selected from any of the 4 formulas Ia, Ib, Ic or Id (clockwise starting in the top left corner) set out below:
  • Z' is H
  • Y is 2,4-dichlorophenyl
  • X is unsubstituted phenyl and R 10 is -OC 2 H 5
  • Z may not be CH 3
  • the following proviso applies: If Z 1 is H 1 Y is 2,4-dibromophenyl, X is unsubstituted phenyl and R 10 is -OCzH 5 , then Z may not be CH 3 .
  • proviso applies:
  • Z' is H
  • Y is 2-chloro-4-trifluoromethyl-phenyl
  • X is unsubstituted phenyl and R 10 is -
  • Z' is H
  • Y is 2,4-dichlorophenyl
  • X is 4-Chloro-phenyl
  • R 10 is -OC 2 H 5
  • Z may not be CH 3 .
  • proviso applies:
  • Z' is H
  • Y is 4-chloro-2-trifluoromethyl-phenyl
  • X is unsubstituted phenyl and R 10 is -
  • R 9 may not be phenyl. In another embodiment the following proviso applies:
  • R 9 may not be phenyl.
  • a "mono- or polycyclic ring-system” means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed. The rings of the mono- or polycyclic ring-sytem are preferably 5- or 6-membered.
  • aryl is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or monosubstituted or polysubstituted.
  • cycloalkyl radical or group is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or mono- or polysubstituted.
  • C 3-4 - cycloalkyl represents C 3 - or C 4 -cycloalkyl, C 3 .
  • 5 -cycloalkyl represents C 3 -, C 4 - or C 5 -cycloalkyl
  • C 3 - 6 -cycloalkyl represents C 3 -, C 4 -, C 5 - or C 6 -cycloalkyl
  • C ⁇ r-cycloalkyl represents C 3 -, C 4 -, C 5 -, C 6 - or C 7 -cycloalkyl
  • C ⁇ -cycloalkyl represents C 3 -, C 4 -, C 5 -, C 6 -, C 7 - or C 8 -cycloalkyl
  • C 4- 5 -cycloalkyl represents C 4 - or C 5 -cycloalkyl
  • C 4-6 -CyClOa Iky I represents C 4 -, C 5 - or C 6 - cycloalkyl
  • C ⁇ -cycloalkyl represents C 4 -, C 5 -, C 6 - or C 7 -cycloalkyl, C
  • cycloalkyls also in particular fall under the term cycloalkyl as long as the cycloalkyl is not an aromatic system.
  • the cycloalkyl radicals are preferably cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl.
  • heterocyclic ring system is understood as meaning heterocyclic ring systems which contain one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring or ringsystem, and can also be mono- or polysubstituted.
  • the ringsystem may consist either of only one saturated or unsaturated or even aromatic ring or may consist of 2, 3 or 4 saturated or unsaturated or even aromatic rings, which are condensed in that between two or more of the rings ring members are shared.
  • heterocyclyls examples which may be mentioned from the group of heterocyclyls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, imidazo-thiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.
  • alkyl a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(O)-C 1-6 . alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(O)-O-C 1 . 6 -alkyl; a substituted or unsubstituted phenyl.
  • monosubstituted means the substitution of exactly one hydrogen radical
  • polysubstituted means the substitution of more than one hydrogen radical with “polysubstituted”radicals being understood as meaning that the replacement takes effect both on different and on the same atoms several times with the same or different substituents. Therefore, “optionally at least monsubstituted” means either “not substituted” (which is the same as “unsubstituted”) if the option is not fulfilled, “monosubstituted” or "polysubstituted”.
  • aryl radical, cycloalkyl radical, or heterocyclyl radical "condensed with” is understood as meaning that the ring-system of the aryl radical, the cycloalkyl radical, or the heterocyclyl radical is sharing two atoms (one) of its ring(s) with a ring of the mono- or polycyclic ring-system it is condensed with.
  • alkyl alkyl radical or group is understood as meaning saturated, linear or branched hydrocarbons, which can be unsubstituted or mono- or polysubstituted.
  • saturated alkyl encompasses e.g. -CH 3 and -CH 2 -CH 3 .
  • d -2 -alkyl represents C 1 - or C 2 -alkyl
  • Ci -3 -alkyl represents C 1 -, C 2 - or C 3 -alkyl
  • C ⁇ -alkyl represents Ci-, C 2 -, C 3 - or C 4 -alkyl
  • C 1-5 -alkyl represents C 1 -, C 2 -, C 3 -, C 4 -, or C 5 -alkyl
  • C 1-6 -alkyl represents C 1 -, C 2 -, C 3 -, C 4 -, C 5 - or C 6 -alkyl
  • C 1-7 -alkyl represents C 1 -, C 2 -, C 3 -, C 4 -, C 5 -, C 6 - or C 7 -alkyl
  • C 1-8 -alkyl represents C 1 -, C 2 -, C 3 -, C 4 -, C 5 -, C 6 -, C 7 -
  • the alkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1- dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1- methylpentyl, if substituted also CHF 2 , CF 3 or CH 2 OH etc.
  • substituted in the context of this invention is understood as meaning replacement of at least one hydrogen radical by F, Cl, Br, I, NH 2 , SH or OH; within that "monosubstituted” means the substitution of exactly one hydrogen radical, whereas "polysubstituted” means the substitution of more than one hydrogen radical with “polysubstituted'Yadicals being understood as meaning that the replacement takes effect both on different and on the same atoms several times with the same or different substituents, for example three times on the same C atom, as in the case of CF 3 , or at different places, as in the case of e.g.
  • alkylene is understood as meaning a divalent alkyl group like -CH 2 - or -CH 2 -CH 2 - with (CH 2 J 3 ⁇ being understood as meaning -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 - CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, (CH 2 ) I - 4 is to be understood as meaning - CH 2 -, -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, (CH 2 J 4-5 is to be understood as meaning -CH 2 -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, etc.
  • salt is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
  • a counter-ion a cation or anion
  • complexes of the active compound with other molecules and ions in particular complexes which are complexed via ionic interactions.
  • physiologically acceptable salt means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic- especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
  • physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals.
  • the salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH4, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
  • physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals.
  • the salt formed with a physiologically tolerated acid that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals.
  • physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
  • the compounds of the invention may be in crystalline form or either as free compounds or as solvates and it is intended that those forms are within the scope of the present invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates.
  • solvate is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
  • a polar solvent especially including hydrates and alcoholates, e.g. methanolate.
  • the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon or 15 N-enriched nitrogen are within the scope of this invention.
  • the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I) or, or of its salts, solvates or prodrugs.
  • substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
  • Z is C ⁇ -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • Z' is selected from hydrogen; C 1-4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • X and Y independently represent an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear C 1-3 -alkyl or branched or linear C 1-3 -alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH 1 trifluoromethyl, CHF 2 , CH 2 F, OCHF 2 , trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C 8-2 o-alkyl, heteroaryl, C(O)-aryl, C(
  • R 10 represents OR 8' or NR 8 R 9 , with
  • R 8 representing a hydrogen atom or a branched or linear d- 4 -alkyl group
  • R 8 representing a hydrogen atom or a branched or linear C 1-3 -alkyl group
  • R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with
  • R 5 , R 6 and R 7 which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br 1 I, OH, SH, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
  • Z is C 1-4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • Z" is selected from hydrogen; Ci- 4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • X and Y independently represent an phenyl, thienyl, naphtyl or pyridyl, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear C 1-3 -alkyl or branched or linear d -3 -alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF 2 , CH 2 F, OCHF 2 , trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C 8-2 o-alkyl, heteroaryl, C(O)-
  • R 10 represents OR 8' or NR 8 R 9 , with
  • R 8 representing a hydrogen atom or a branched or linear C 1-4 -alkyl group
  • R 8 representing a hydrogen atom or a branched or linear C 1-3 -alkyl group
  • R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with
  • R 5 , R 6 and R 7 which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2
  • R 8 and R 9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl
  • substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
  • Z is CH 3 or C 2 H 5 ;
  • Z' is hydrogen
  • X and Y independently represent phenyl or thienyl; preferably Y representing phenyl, while X represents phenyl or thienyl; more preferably X and Y representing phenyl; and/or
  • R 10 represents OR 8' with
  • R 8 representing a hydrogen atom or a branched or linear C 1-4 -alkyl group, preferably hydrogen, CH 3 or C 2 H 5 ;
  • R 10 represents NR 8 R 9 , with
  • R 8 representing a hydrogen atom or a branched or linear C 1-3 -alkyl group, preferably hydrogen
  • R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical.
  • R 8 and R 9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical.
  • Z is C 1-4 -AIk ⁇ 1 substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • R 1U represents OR 8 8 ' ⁇ o,r M NDR8 B R D 9 a , with
  • R 8 representing a hydrogen atom or a branched or linear C 1-4 -alkyl group
  • R 8 representing a hydrogen atom or a branched or linear d- 3 -alkyl group
  • R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with
  • R 5 , R 6 and R 7 which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I 1 OH 1 SH 1 C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I 1 OH 1 SH, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F 1 OCF 3 , a keto-group, NO 2 or NH 2 ;
  • R 11 , R 12 , R 13 and R 14 independently of one another represent:
  • substituted pyrazoline compounds of the invention are compounds according to general formula II, wherein
  • R 11 , R 12 , R 13 and R 14 independently of one another represent H, CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl 1 Br, I CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably R 11 , R 12 , R 13 and R 14 independently of one another represent H 1 OH, OCH 3 , F 1 Cl 1 Br 1 I, CF 3 , CHF 2 or OCF 3 ; and/or
  • Z is CH 3 or C 2 H 5 ;
  • R 10 represents OR 8' with
  • R 8 representing a hydrogen atom or a branched or linear C 1-4 -alkyl group, preferably hydrogen, CH 3 or C 2 H 5 ;
  • R 10 represents NR 8 R 9 , with
  • R 8 representing a hydrogen atom or a branched or linear C 1-3 -alkyl group, preferably hydrogen
  • R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical.
  • R 8 and R 9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical.
  • the substituted pyrazoline compounds of the invention are compounds according to general formula III
  • Z is C 1-4 -AIkVl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • R 8 represents a hydrogen atom or a branched or linear C 1-3 -alkyl group, while R 9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with;
  • R 5 , R 6 and R 7 which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F 1 Cl, Br, I, OH, SH, C 1-4 alkyl, C ⁇ alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • R 11 , R 12 , R 13 and R 14 independently of one another represent:
  • substituted pyrazoline compounds of the invention are compounds according to general formula III, wherein
  • R 11 , R 12 , R 13 and R 14 independently of one another represent H, CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl, Br, I CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably R 11 , R 12 , R 13 and R 14 independently of one another represent H, OH, OCH 3 , F, Cl, Br, I, CF 3 , CHF 2 or OCF 3 ; and/or
  • Z is CH 3 or C 2 H 5 ;
  • R 8 represents a hydrogen atom
  • R 9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C ⁇ alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 .
  • Z is C 1-4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • R 9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with;
  • R 5 , R 6 and R 7 which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl, Br, I 1 OH, SH, C M alkyl, C ⁇ alkoxy, CF 3 , CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ;
  • R 11 and R 12 independently of one another represent:
  • substituted pyrazoline compounds of the invention are compounds according to general formula IV, wherein
  • R 11 and R 12 independently of one another represent H, CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl, Br, I CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably R 11 , R 12 , R 13 and R 14 independently of one another represent H, OH, OCH 3 , F, Cl, Br, I 1 CF 3 , CHF 2 or OCF 3 ; and/or
  • Z is CH 3 or C 2 H 5 ; and/or R 9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H, F, Cl 1 Br 1 I 1 OH, SH 1 C 1-4 alkyl, C 1-4 alkoxy, CF 3 , CHF 2 , CH 2 F 1 OCF 3 . a keto-group, NO 2 or NH 2 .
  • substituted pyrazoline compounds of the invention are compounds according to general formula IV 1 wherein
  • R 11 and R 12 independently of one another represent H 1 CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl, Br 1 I CF 3 .
  • CHF 2 , CH 2 F 1 OCF 3 , OCHF 2 preferably represent H, OH, OCH 3 , F 1 Cl, Br, I, CF 3 , CHF 2 or OCF 3 ; more preferably represent Br 1 Cl 1 OH, OCH 3 , or H; most preferably represent H; and/or
  • Z is CH 3 or C 2 H 5 ; preferably is CH 3 ; and/or
  • R 9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R 5 , R 6 and R 7 , which can be the same or different, with R 5 , R 6 and R 7 being independently from one another selected from H 1 F, Cl, Br 1 I 1 OH 1 SH 1 C 1-4 alkyl, Ci -4 alkoxy, CF 3 . CHF 2 , CH 2 F, OCF 3 , a keto-group, NO 2 or NH 2 ; preferably represents an unsubstituted aryl radical, cycloalkyl radical, or heterocyclyl radical.
  • substituted pyrazoline compounds of the invention are compounds according to general formula IV, wherein
  • R 11 and R 12 independently of one another represent H 1 CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH 1 F, Cl, Br 1 1 CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably represent H, OH, OCH 3 , F, Cl 1 Br 1 I, CF 3 , CHF 2 or OCF 3 ; more preferably represent Br, Cl, OH, OCH 3 , or H; most preferably represent H; and
  • Z is CH 3 or C 2 H 5 ; preferably is CH 3 ; and R 9 represents
  • a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH 2 )-, -(CH 2 HCH 2 )-, -(CH 2 )- (CH 2 HCH 2 )- or -CH CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-buty
  • a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH 2 )-, -(CH 2 HCH 2 )-, -(CH 2 HCH 2 HCH 2 )- or -CH CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting Of -CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
  • R 9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or of the group consisting of
  • R 9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
  • substituted pyrazoline compounds of the invention are compounds according to general formula I, II, III, and IV, wherein
  • R 9 represents
  • a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH 2 )-, -(CI-I 2 HCH 2 )-, -(CH 2 )- (CH 2 HCH 2 )- or -CH CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, ter
  • a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH 2 )-, -(CH 2 HCH 2 )-, -(CH 2 HCH 2 HCH 2 )- or -CH CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of -CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
  • radicals which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;
  • R 9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
  • Z is C 1-4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • R 8 represents a hydrogen atom or a branched or linear C 1-4 -alkyl group
  • R 11 , R 12 , R 13 and R 14 independently of one another represent:
  • H branched or linear d- 3 -alkyl or branched or linear C 1-3 -alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF 2 , CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C 8-2 o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C 1-20 -alkyl;
  • substituted pyrazoline compounds of the invention are compounds according to general formula V, wherein
  • R 11 , R 12 , R 13 and R 14 independently of one another represent H, CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl, Br, I CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably R 11 , R 12 , R 13 and R 14 independently of one another represent H, OH, OCH 3 , F, Cl, Br, I, CF 3 , CHF 2 or OCF 3 ; and/or
  • Z is CH 3 or C 2 H 5 ;
  • R 8 represents a hydrogen atom, CH 3 or C 2 H 5 .
  • Z is Ci- 4 -Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
  • R 8 represents a hydrogen atom or a branched or linear C 1-4 -alkyl group
  • R 11 and R 12 independently of one another represent:
  • H branched or linear C 1-3 -alkyl or branched or linear d -3 -alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH 1 trifluoromethyl, CHF 2 , CH 2 F 1 OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C 8-2 o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C 1-20 -alkyl;
  • substituted pyrazoline compounds of the invention are compounds according to general formula Vl, wherein
  • R 11 and R 12 independently of one another represent H, CH 3 , C 2 H 5 , C 3 H 7 , OCH 3 , OC 2 H 5 , OH, SH, F, Cl, Br 1 I CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 ; preferably represent H, OH, OCH 3 , F, Cl, Br, I, CF 3 , CHF 2 or OCF 3 ; more preferably represent Br, Cl, OH, OCH 3 , or H; most preferably represent H; and/or
  • Z is CH 3 or C 2 H 5 ; preferably is CH 3 ; and/or
  • R 8 is hydrogen, CH 3 or C 2 H 5 ; preferably is hydrogen or C 2 H 5 .
  • substituted pyrazoline compounds of general formula (I) themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractunalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis.
  • the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) and stereoisomers thereof, wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium.
  • Suitable reaction media include, for example, any of the ones given above.
  • Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid
  • suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
  • the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) or stereoisomers thereof, wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium.
  • suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NH n R 4-O ] + , wherein n is 0, 1 , 2, 3 or 4 and R represents a branched or unbranched C 1-4 -alkyl- radical.
  • suitable reaction media are, for example, any of the ones given above.
  • Solvates preferably hydrates, of the substituted pyrazoline compounds of general formula (I), of corresponding stereoisomers, of corresponding N-oxides or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • Substituted pyrazoline compounds of general formula I which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
  • substituted pyrazoline compounds as used herein is to be understood as encompassing derivatives such as ethers, esters and complexes of these compounds as well.
  • derivatives as used in this application is defined here as meaning a chemical compound having undergone a chemical derivation starting from an acting (active) compound to change (ameliorate for pharmaceutical use) any of its physico-chemical properties, especially a so-called prodrug, e.g. their esters and ethers. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002). The respective description is hereby incorporated by reference and forms part of the disclosure.
  • substituted pyrazoline compounds of general formula I given above, their stereoisomers, corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.
  • another aspect of the present invention relates to a medicament comprising at least one substituted pyrazoline compound of general formula I according to the invention described above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
  • X may not be monosubstituted cyclohexene.
  • Another aspect of the present invention is the use of at least one substituted pyrazoline compound of general formula I given above as suitable active substances, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for for the prophylaxis and/or treatment of dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia.
  • pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of dyslipidaemia.
  • pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of metabolic syndrome, preferably also the weight independent aspects of metabolic syndrome.
  • pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of diabetes Type II.
  • use of at least one of the pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients for the preparation of a medicament for the prophylaxis and/or treatment of obesity.
  • At least one of the respective substituted pyrazoline compounds optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity and/or type Il diabetus mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.
  • Another aspect of the present invention is a method of treating dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia in a patient in need thereof with at least one substituted pyrazoline compound of general formula I given above as suitable active substances, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients.
  • dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity especially dyslipidaemia.
  • the medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the medicament can be produced by standard procedures known to those skilled in the art, e.g. from the table of contents of "Pharmaceutics: The Science of Dosage Forms", Second Edition, Aulton, M. E. (ED. Churchill Livingstone, Edinburgh (2002); “Encyclopedia of Pharmaceutical Technology", Second Edition, Swarbrick, J. and Boylan J. C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics", Fourth Edition, Banker G. S. and Rhodes CT.
  • composition of the medicament may vary depending on the route of administration.
  • the medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols.
  • Conventional pharmaceutical excipients for injection such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions.
  • These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form.
  • These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, granules, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • the multiparticulate forms, such as pellets or granules may e.g. be filled into a capsule, compressed into tablets or suspended in a suitable liquid.
  • Suitable controlled release formulations, materials and methods for their preparation are known from the prior art, e.g. from the table of contents of "Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology”, Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000); "Controlled Drug Delivery", VoI, I, Basic Concepts, Bruck, S.D. (Ed.), CRD Press Inc., Boca Raton (1983) y de Takada, K.
  • Medicaments according to the present invention may also comprise an enteric coating, so that their dissolution is dependent on pH-value. Due to said coating the medicament can pass the stomach undissolved and the respective nitro-subsituted phenyl-piperazine compound is liberated in the intestinal tract.
  • the enteric coating is soluble at a pH value of 5 to 7.5. Suitable materials and methods for the preparation are known from the prior art.
  • the medicaments according to the present invention may contain 1 -60 % by weight of one or more substituted pyrazoline compounds as defined herein and 40-99 % by weight of one or more auxiliary substances (additives).
  • liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
  • compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans may preferably be in the range fromi to 2000, preferably 1 to 1500, more preferably 1 to 1000, even more preferably 1 to 150 milligrams of active substance to be administered during one or several intakes per day.
  • the filtrate is concentrated and purified using a Combiflah system from Isco, eluting with cyclohexane and ethyl acetate (in a gradient program until 10% AcOEt), to obtain ethyl 5-(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3- carboxylate (2.47 g, 50 % yield).
  • H 2 N-R compound (amine or hydrazine) (1.52 mmoles) and /V, ⁇ /-diisopropylethylamine (DIPEA) (0.522 mL, 3.05 mmol) were dissolved in methylene chloride (10 mL).
  • DIPEA diisopropylethylamine
  • the resulting mixture was ice-cooled down to 0 0 C and Oa solution of 5-(4- chlorophenyl)-1 -(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carbonyl chloride (0.51O g, 1.27 mmoles), obtained in the former step, in methylene chloride (2 mL) was added dropwise.
  • hepatic microsomes were prepared from the Wistar rats. Enzyme inhibition experiments were performed in presence of 18 ⁇ M [ 14 C]-Palmitoyl CoA as substrate.
  • the vehicle used was 1% DMSO.
  • Compounds to be tested were present at various concentrations and the incubation buffer used was 0.2 M Phosphate buffer, pH 7.4 at 25°C. After a 15 minutes preincubation period at 37 0 C an incubation period of 10 minutes at 37°C followed. Quantification of [ 14 C]Cholesterol ester was done by column chromatography.
  • the reference compound used was Lovastatin, which has a reported IC 50 of 29 ⁇ M.

Abstract

The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia. Formula (I).

Description

Substituted pyrazoline compounds with ACAT Inhibition Activity, their preparation and use as medicaments
The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.
It is now abundantly clear that abundant access to highly palatable, calorie-dense, low-cost Westernised diets is producing an explosion in the prevalence of dyslipidaemia, obesity, particularly central adiposity, insulin resistance/impaired glucose tolerance and/or Type 2 diabetes (Zephier et al, 1997; International Diabetes Federation, 2003; Grundy, 2004; Deedwania, 2004). Moreover, when occurring in combination, these cardio-metabolic risk factors comprise the Metabolic Syndrome as defined for example by expert bodies, eg World Health Organisation (WHO, 1999) and the National Cholesterol Education Programme - Third Adult Treatment Panel (NCEP ATP III, 2001 ) and the International Diabetes Federation (IDF, 2005).
The term "dyslipidaemia" is defined both as a disease entity in its own right and as a component of the Metabolic Syndrome. Thus, within the context of the various definitions of the Metabolic Syndrome, certain lipid abnormalities are specifically defined as follows :
According to world Health Organisation (WHO) (1999) :
• Raised plasma triglycerides (> 1.7 mmol/L; 150 mg/dL).
• Low plasma HDL-cholesterol (< 0.9 mmol/L, 35 m/dL men; < 1.0 mmol/L, 39 mg/dL women).
According to National Cholesterol Education Programme (NCEP) Adult Treatment Panel (ATP) III (2002) :
• Raised plasma triglycerides (≥ 1.7 mmol/L; 150 mg/dL).
• Low plasma HDL-cholesterol (< 1.03 mmol/L, 40 mg/dL men; < 1.29 mmol/L, 50 mg/dL women).
According to International Diabetes Federation (IDF) (2005) : • Raised serum triglycerides (≥ 1.7 mmol/L; 150 mg/dL) or specific treatment for this lipid abnormality.
• Reduced plasma HDL-cholesterol (< 1.03 mmol/L, 40 mg/dL men; 1.29 mmol/L, 50 mg/dL women) or specific treatment for this abnormality.
In addition to the above lipid abnormalities pertaining to definitions of the Metabolic Syndrome, "dyslipidaemia" also encompasses the following disorders as described by the NCEP in their ATP III Guidelines (NCEP ATP III, 2002): heterozygous familial hypercholesterolaemia (FH), homozygous familial hypercholesterolaemia (FH)1 familial defective apolipoprotein B-100 (FDB), polygenic hypercholesterolaemia hypertriglyceridaemia including familial combined hyperlipidaemia, familial hypertriglyceridaemia and familial dysbetalipoproteinaemia, low HDL-cholesterol (with or without hypertriglyceridaemia), diabetic dyslipidaemia (ie atherogenic dyslipidaemia in persons with Type 2 diabetes), elevated LDL-cholesterol and atherogenic dyslipidaemia. Other secondary dyslipidaemias include, but are not limited to, those evoked by hypothyroidism, nephrotic syndrome and other renal disorders, obstructive liver disease and protease-inhibitor induced dyslipidaemia.
As also stated in the NCEP ATP III Guidelines (2002), the necessity to treat dyslipidaemia in patients is defined not only by the serum or plasma concentrations of individual lipids, but also by the coexistence of lipid abnormalities with other cardiovascular risk factors and/or related disorders, eg hypertension, cardiovascular disease and Type 2 diabetes, the patient's medical history, also whether or not the patient has a history of cerebrovascular or cardiovascular adverse events, eg myocardial infarction, congestive heart failure, angina and/or haemorrhagic or thromboembolic stroke. Such clinical factors are well known to those skilled in the art and are taken into account in the decision whether or not to prescribe medications to treat dyslipidaemia.
In the present invention, all of the above indications are included under the term "dyslipidaemia".
It is also well known that obesity and visceral adiposity are important metabolic consequences of the excessive consumption of highly palatable, calorie-dense foods (Zephier et al, 1997; International Diabetes Federation, 2005; Grundy, 2004; Deedwania, 2004), and in some instances, from cravings for and binge eating, of specific palatable food sources (White et al, 2002; Phelan & Whadden, 2002; Yanovski, 2003; White & Grilo, 2005). Dyslipaemia, with or without obesity, is major cause of insulin resistance and a key driver of the progression of pre-diabetes (insulin resistance and/or impaired glucose tolerance) to Type 2 diabetes (Boden & Laakso, 2004; Bays et al, 2004; IDF, 2005). Furthermore, there is also a high degree of association between Type 2 diabetes and dyslipidaemia whereby the latter is characterised by raised plasma levels of small, dense LDL-cholesterol particles, elevated triglycerides and low concentrations of HDL-cholesterol particles (Boden & Laakso, 2004).
The Metabolic Syndrome consists of a cluster of cardio-metabolic risk factors, but obesity, central adiposity, lipid abnormalities, (raised serum triglycerides, low serum HDL-cholesterol) and impaired glucose tolerance or Type 2 diabetes are core symptoms of the Metabolic Syndrome, irrespective of whether a diagnosis of is made according to the criteria defined by the World Health Organisation (WHO, 1999), the National Cholesterol Education Programme - Third Adult Treatment Panel (NCEP ATP III, 2001 ) or the International Diabetes Federation (IDF, 2005).
One Enzyme playing an important role in the metabolism of lipids and, which is thus an interesting target for the effects on dyslipidaemia is Acyl CoA-Cholesterol Acyltransferase (herafter also called in the normal abbreviation: ACAT).
Even though with the pharmaceutical class of statins, which are as such quite potent lipid lowering agents acting by inhibitng HMG-CoA reductase and are useful for the prophylaxis and/or treatment of cardiovascular diseases, there are safety concern related to the use of statins. One of them is the development of rhabdomyolysis, the pathological breakdown of skeletal muscle, which may lead to acute renal failure when muscle breakdown products damage the kidney. Consequently, there is still a big demand for potent therapeutic agents to treat dyslipidaemia, possibly, showing less incidents of undesired side effects of statins, or at least less pronounced.
Thus, it was an object of the present invention to provide novel compounds for use as active substances in medicaments. In particular, these active substances should act on or inhibit ACAT and thus be suitable for the treatment of dyslipidaemia.
Said object was achieved by providing the substituted pyrazoline compounds of general formula I given below, their stereoisomers, corresponding salts and corresponding solvates thereof. It has been found that these compounds show a high inhibition of ACAT and therefore seem suitable for the prophylaxis and/or treatment of dyslipidaemia, but also diabetes Type II, Metabolic Syndrome or obesity.
Thus, in one of its aspects the present invention relates to a substituted pyrazoline compound of general formula I,
Figure imgf000005_0001
wherein
Z is Ci-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z' is selected from hydrogen; C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an optionally at least monsubstituted mono- or polycyclic ring-system;
FT represents OR" or NRBRa, with
R8 representing a hydrogen atom or a branched or linear C^-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, while R9 is representing an optionally at least monsubstituted mono- or polycyclic ring-system; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
Formula I is also covering the diastereoisomers and thus may also be selected from any of the 4 formulas Ia, Ib, Ic or Id (clockwise starting in the top left corner) set out below:
Figure imgf000006_0001
In one embodiment the following proviso applies:
If Z' is H, Y is p-toluol and R10 is -OCH3, then X may not be monosubstituted cyclohexene. In another embodiment the following proviso applies:
If Z' is H, Y is 2,4-dichlorophenyl, X is unsubstituted phenyl and R10 is -OC2H5, then Z may not be CH3. In a further embodiment the following proviso applies: If Z1 is H1 Y is 2,4-dibromophenyl, X is unsubstituted phenyl and R10 is -OCzH5, then Z may not be CH3. In another further embodiment the following proviso applies:
If Z' is H, Y is 2-chloro-4-trifluoromethyl-phenyl, X is unsubstituted phenyl and R10 is -
OC2H5, then Z may not be CH3. In another embodiment the following proviso applies:
If Z' is H, Y is 2,4-dichlorophenyl, X is 4-Chloro-phenyl and R10 is -OC2H5, then Z may not be CH3. In another further embodiment the following proviso applies:
If Z' is H, Y is 4-chloro-2-trifluoromethyl-phenyl, X is unsubstituted phenyl and R10 is -
OC2H5, then Z may not be CH3. In another embodiment the following proviso applies:
If Z' is H, and X and Y are phenyl and R10 is NR8R9, R9 may not be phenyl. In another embodiment the following proviso applies:
If R10 is NR8R9, R9 may not be phenyl.
A "mono- or polycyclic ring-system" according to the present invention means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed. The rings of the mono- or polycyclic ring-sytem are preferably 5- or 6-membered.
An "aryl", "aryl radical" or group is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or monosubstituted or polysubstituted.
In the context of this invention "cycloalkyl radical" or group is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or mono- or polysubstituted. Furthermore, C3-4- cycloalkyl represents C3- or C4-cycloalkyl, C3.5-cycloalkyl represents C3-, C4- or C5-cycloalkyl, C3-6-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl, C^r-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl, C^-cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl, C4- 5-cycloalkyl represents C4- or C5-cycloalkyl, C4-6-CyClOa Iky I represents C4-, C5- or C6- cycloalkyl, C^-cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl, C^-cycloalkyl represents C4-, C5-, C6- C7- or C8-cycloalkyl C5-6-CyClOa I kyl represents C5- or C6-cycloalkyl and C5-7- cycloalkyl represents C5-, C6- or C7-cycloalkyl. However, mono- or polyunsaturated, preferably monounsaturated, cycloalkyls also in particular fall under the term cycloalkyl as long as the cycloalkyl is not an aromatic system. The cycloalkyl radicals are preferably cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl.
A "heterocyciyl", a "heterocyclyl radical" or group or "heterocyclic ring system" is understood as meaning heterocyclic ring systems which contain one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring or ringsystem, and can also be mono- or polysubstituted. The ringsystem may consist either of only one saturated or unsaturated or even aromatic ring or may consist of 2, 3 or 4 saturated or unsaturated or even aromatic rings, which are condensed in that between two or more of the rings ring members are shared. Examples which may be mentioned from the group of heterocyclyls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, imidazo-thiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.
In connection with mono- or polycyclic ring-system, aryl radical, cycloalkyl radical, or heterocyclyl radical, "substituted" is understood - unless defined otherwise - as meaning replacement of at least one hydrogen radical on the ring-system of the mono- or polycyclic ring-system, the aryl radical, the cycloalkyl radical, or the heterocyclyl radical by OH, SH, =0, halogen (F, Cl, Br, I), CN, NO2, COOH; NRxRy, with Rx and Ry independently being either H or a saturated or unsaturated, linear or branched, substituted or unsubstituted d-β-alkyl; by a saturated or unsaturated, linear or branched, substituted or unsubstituted C1-6-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -O-C1-6.alkyl (alkoxy); a saturated or unsaturated, linear or branched, substituted or unsubstituted -S-C1-6. alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(O)-C1-6. alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(O)-O-C1. 6-alkyl; a substituted or unsubstituted phenyl. Within that "monosubstituted" means the substitution of exactly one hydrogen radical, whereas "polysubstituted" means the substitution of more than one hydrogen radical with "polysubstituted"radicals being understood as meaning that the replacement takes effect both on different and on the same atoms several times with the same or different substituents. Therefore, "optionally at least monsubstituted" means either "not substituted" (which is the same as "unsubstituted") if the option is not fulfilled, "monosubstituted" or "polysubstituted".
In connection with aryl radical, cycloalkyl radical, or heterocyclyl radical, "condensed with" is understood as meaning that the ring-system of the aryl radical, the cycloalkyl radical, or the heterocyclyl radical is sharing two atoms (one) of its ring(s) with a ring of the mono- or polycyclic ring-system it is condensed with.
In the context of this invention, "alkyl", "alkyl radical" or group is understood as meaning saturated, linear or branched hydrocarbons, which can be unsubstituted or mono- or polysubstituted. Thus unsaturated alkyl is understood to encompass alkenyl and alkinyl groups, like e.g. -CH=CH-CH3 or -C=C-CH3, while saturated alkyl encompasses e.g. -CH3 and -CH2-CH3. In these radicals, d-2-alkyl represents C1- or C2-alkyl, Ci-3-alkyl represents C1-, C2- or C3-alkyl, C^-alkyl represents Ci-, C2-, C3- or C4-alkyl, C1-5-alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl, C1-6-alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl, C1-7-alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl, C1-8-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or Cβ-alkyl, C1-10-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl and C1-18-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl. The alkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1- dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1- methylpentyl, if substituted also CHF2, CF3 or CH2OH etc.
In connection with alkylene, or alkyl radical or group - unless defined otherwise - the term "substituted" in the context of this invention is understood as meaning replacement of at least one hydrogen radical by F, Cl, Br, I, NH2, SH or OH; within that "monosubstituted" means the substitution of exactly one hydrogen radical, whereas "polysubstituted" means the substitution of more than one hydrogen radical with "polysubstituted'Yadicals being understood as meaning that the replacement takes effect both on different and on the same atoms several times with the same or different substituents, for example three times on the same C atom, as in the case of CF3, or at different places, as in the case of e.g. -CH(OH)- CH=CH-CHCI2. Therefore, "optionally at least monsubstituted" means either "not substituted" if the option is not fulfilled, "monosubstituted" or "polysubstituted". The term "alkylene" is understood as meaning a divalent alkyl group like -CH2- or -CH2-CH2- with (CH2J3^ being understood as meaning -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2- CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-CH2-CH2-, (CH2)I-4 is to be understood as meaning - CH2-, -CH2-CH2-, -CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-, (CH2J4-5 is to be understood as meaning -CH2-CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-CH2-, etc. An "alkylene" may also be unsaturated.
The term "salt" is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes which are complexed via ionic interactions.
The term "physiologically acceptable salt" means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic- especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
These physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals. The salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH4, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
These physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals. By this is understood in particular, in the context of this invention, the salt formed with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid. The compounds of the invention may be in crystalline form or either as free compounds or as solvates and it is intended that those forms are within the scope of the present invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates. The term "solvate" according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon or 15N-enriched nitrogen are within the scope of this invention.
The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I) or, or of its salts, solvates or prodrugs.
In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
Z is C^-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z' is selected from hydrogen; C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH1 trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-Ci-20-alkyl;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear d-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br1 I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z" is selected from hydrogen; Ci-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an phenyl, thienyl, naphtyl or pyridyl, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear C1-3-alkyl or branched or linear d-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; or R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl1 Br, I, OH1 SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula I, wherein
Z is CH3 or C2H5; and/or
Z' is hydrogen; and/or
X and Y independently represent phenyl or thienyl; preferably Y representing phenyl, while X represents phenyl or thienyl; more preferably X and Y representing phenyl; and/or
R10 represents OR8' with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, preferably hydrogen, CH3 or C2H5;
or
R10 represents NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, preferably hydrogen; and
R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical.
In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula Il
Figure imgf000015_0001
wherein
Z is C1-4-AIk^1 substituted or unsubstituted, branched or linear, saturated or unsaturated;
R1U represents OR 88' Λ o,r M NDR8BRD9a, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear d-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I1 OH1 SH1 C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I1 OH1 SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F1 OCF3, a keto-group, NO2 or NH2;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-20-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
As the general formula Il also covers the enantiomers it may also be in the form of general formulas Ma and Mb.
Figure imgf000017_0001
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula II, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl1 Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H1 OH, OCH3, F1 Cl1 Br1 I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R10 represents OR8' with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, preferably hydrogen, CH3 or C2H5;
or
R10 represents NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, preferably hydrogen; and
R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical. In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula III
Figure imgf000018_0001
wherein
Z is C1-4-AIkVl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear C1-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
or R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F1 Cl, Br, I, OH, SH, C1-4alkyl, C^alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-Ci-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
As the general formula III also covers the enantiomers it may also be in the form of general formulas MIa and IMb:
Figure imgf000020_0001
(Ilia) nib)
In a preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula III, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R8 represents a hydrogen atom;
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C^alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula IV
Figure imgf000021_0001
wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I1 OH, SH, CMalkyl, C^alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
R11 and R12 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl; optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
As the general formula Il also covers the enantiomers it may also be in the form of general formulas IVa and IVb.
Figure imgf000022_0001
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula IV, wherein
R11 and R12 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I1 CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl1 Br1 I1 OH, SH1 C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F1 OCF3. a keto-group, NO2 or NH2.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula IV1 wherein
R11 and R12 independently of one another represent H1 CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br1 I CF3. CHF2, CH2F1 OCF3, OCHF2; preferably represent H, OH, OCH3, F1 Cl, Br, I, CF3, CHF2 or OCF3; more preferably represent Br1 Cl1 OH, OCH3, or H; most preferably represent H; and/or
Z is CH3 or C2H5; preferably is CH3; and/or
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H1 F, Cl, Br1 I1 OH1 SH1 C1-4alkyl, Ci-4alkoxy, CF3. CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; preferably represents an unsubstituted aryl radical, cycloalkyl radical, or heterocyclyl radical.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula IV, wherein
R11 and R12 independently of one another represent H1 CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH1 F, Cl, Br1 1 CF3, CHF2, CH2F, OCF3, OCHF2; preferably represent H, OH, OCH3, F, Cl1 Br1 I, CF3, CHF2 or OCF3; more preferably represent Br, Cl, OH, OCH3, or H; most preferably represent H; and
Z is CH3 or C2H5; preferably is CH3; and R9 represents
a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2)- (CH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1, 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n- pentyl, 2-pentyl and n-hexyl;
a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2HCH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting Of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
or a radical selected from the group consisting of
Figure imgf000025_0001
Figure imgf000025_0002
Figure imgf000025_0004
which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals; preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or of the group consisting of
Figure imgf000027_0001
Figure imgf000027_0002
Figure imgf000027_0003
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals; more preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
Figure imgf000028_0001
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula I, II, III, and IV, wherein
R9 represents
a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH2)-, -(CI-I2HCH2)-, -(CH2)- (CH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n- pentyl, 2-pentyl and n-hexyl;
a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2HCH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
or a radical selected from the group consisting of
Figure imgf000029_0001
Figure imgf000029_0002
Figure imgf000029_0003
Figure imgf000029_0004
which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;
more preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
Figure imgf000030_0001
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are selected from the group consisting of:
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid piperidin-1-ylamide; hydrochloride;
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid azepan-1-ylamide; hydrochloride;
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid cycloheptylamide;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula V
Figure imgf000031_0001
(V)
wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear C1-4-alkyl group;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear d-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof. As the general formula V also covers the enantiomers it may also be in the form of general formulas Va and Vb.
Figure imgf000032_0001
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula V, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R8 represents a hydrogen atom, CH3 or C2H5.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula Vl
Figure imgf000033_0001
(Vl)
wherein
Z is Ci-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear C1-4-alkyl group;
R11 and R12 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear d-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH1 trifluoromethyl, CHF2, CH2F1 OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
As the general formula Vl also covers the enantiomers it may also be in the form of general formulas Via and VIb.
Figure imgf000034_0001
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds according to general formula Vl, wherein
R11 and R12 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br1 I CF3, CHF2, CH2F, OCF3, OCHF2; preferably represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; more preferably represent Br, Cl, OH, OCH3, or H; most preferably represent H; and/or
Z is CH3 or C2H5; preferably is CH3; and/or
R8 is hydrogen, CH3 or C2H5; preferably is hydrogen or C2H5.
In another preferred embodiment of the invention the substituted pyrazoline compounds of the invention are compounds selected from the group consisting of:
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid; • 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid ethyl ester;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
The afore mentioned reactions involving the synthesis of the 4,5-dihydro-pyrazole ring or the reaction of a compound comprising said ring are carried out under an inert atmosphere, preferably nitrogen or argon, to avoid oxidation of the ring-system.
During the processes described above the protection of sensitive groups or of reagents may be necessary and/or desirable. The introduction of conventional protective groups as well as their removal may be performed by methods well-known to those skilled in the art.
If the substituted pyrazoline compounds of general formula (I) themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractunalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis.
In a further aspect the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) and stereoisomers thereof, wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
In yet a further aspect the present invention also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) or stereoisomers thereof, wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NHnR4-O]+, wherein n is 0, 1 , 2, 3 or 4 and R represents a branched or unbranched C1-4-alkyl- radical. Suitable reaction media are, for example, any of the ones given above.
Solvates, preferably hydrates, of the substituted pyrazoline compounds of general formula (I), of corresponding stereoisomers, of corresponding N-oxides or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
Substituted pyrazoline compounds of general formula I, which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
Those skilled in the art understand that the term substituted pyrazoline compounds as used herein is to be understood as encompassing derivatives such as ethers, esters and complexes of these compounds as well. The term "derivatives" as used in this application is defined here as meaning a chemical compound having undergone a chemical derivation starting from an acting (active) compound to change (ameliorate for pharmaceutical use) any of its physico-chemical properties, especially a so-called prodrug, e.g. their esters and ethers. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002). The respective description is hereby incorporated by reference and forms part of the disclosure.
The purification and isolation of the inventive substituted pyrazoline compounds of general formula (I), of a corresponding stereoisomer, or salt, or N-oxide, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.
The substituted pyrazoline compounds of general formula I given above, their stereoisomers, corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments. Thus, another aspect of the present invention relates to a medicament comprising at least one substituted pyrazoline compound of general formula I according to the invention described above, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof, and optionally at least one physiologically acceptable auxiliary agent.
In one embodiment the following proviso applies to the substituted pyrazoline compound of general formula I according to the invention:
If Z' is H1 Y is p-toluol and R10 is -OCH3, then X may not be monosubstituted cyclohexene.
Another aspect of the present invention is the use of at least one substituted pyrazoline compound of general formula I given above as suitable active substances, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for for the prophylaxis and/or treatment of dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia.
Also particularly preferred is the use of at least one of the pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of dyslipidaemia.
Also particularly preferred is the use of at least one of the pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of metabolic syndrome, preferably also the weight independent aspects of metabolic syndrome.
Also particularly preferred is the use of at least one of the pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of diabetes Type II. Also particularly preferred is the use of at least one of the pyrazoline compounds as defined herein and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of obesity.
Also particularly preferred is the use of at least one of the respective substituted pyrazoline compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably bulimia, anorexia, cachexia, obesity and/or type Il diabetus mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.
Another aspect of the present invention is a method of treating dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia in a patient in need thereof with at least one substituted pyrazoline compound of general formula I given above as suitable active substances, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients. dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia.
The medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art. The medicament can be produced by standard procedures known to those skilled in the art, e.g. from the table of contents of "Pharmaceutics: The Science of Dosage Forms", Second Edition, Aulton, M. E. (ED. Churchill Livingstone, Edinburgh (2002); "Encyclopedia of Pharmaceutical Technology", Second Edition, Swarbrick, J. and Boylan J. C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics", Fourth Edition, Banker G. S. and Rhodes CT. (Eds.) Marcel Dekker, Inc. New York 2002 y "The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. And Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective descriptions are hereby incorporated by reference and form part of the disclosure. The composition of the medicament may vary depending on the route of administration. The medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions. These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents. The compositions may take any convenient form, such as tablets, pellets, granules, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release. The multiparticulate forms, such as pellets or granules, may e.g. be filled into a capsule, compressed into tablets or suspended in a suitable liquid.
Suitable controlled release formulations, materials and methods for their preparation are known from the prior art, e.g. from the table of contents of "Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology", Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000); "Controlled Drug Delivery", VoI, I, Basic Concepts, Bruck, S.D. (Ed.), CRD Press Inc., Boca Raton (1983) y de Takada, K. and Yoshikawa, H., "Oral Drug Delivery", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon", Encyclopedia of Controlled Drug Delivery, Mathiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 698-728. The respective descriptions are hereby incorporated by reference and form part of the disclosure.
Medicaments according to the present invention may also comprise an enteric coating, so that their dissolution is dependent on pH-value. Due to said coating the medicament can pass the stomach undissolved and the respective nitro-subsituted phenyl-piperazine compound is liberated in the intestinal tract. Preferably the enteric coating is soluble at a pH value of 5 to 7.5. Suitable materials and methods for the preparation are known from the prior art. Typically, the medicaments according to the present invention may contain 1 -60 % by weight of one or more substituted pyrazoline compounds as defined herein and 40-99 % by weight of one or more auxiliary substances (additives).
The liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents. Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
The compositions of the present invention may also be administered topically or via a suppository.
The daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth. The daily dosage for humans may preferably be in the range fromi to 2000, preferably 1 to 1500, more preferably 1 to 1000, even more preferably 1 to 150 milligrams of active substance to be administered during one or several intakes per day.
The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.
The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.
Examples:
CHEMICAL PART
The compounds were prepared following the general approach set out in Scheme 1 :
Figure imgf000041_0001
1 h / 0-5°C
70-80% yield
Figure imgf000041_0002
50 % yield
Figure imgf000041_0003
85 % yield
Figure imgf000041_0004
(quant)
70-90% yield
In a more specific way the chemical examples were generally prepared as follows: Cl
Figure imgf000042_0001
yield
Figure imgf000042_0002
Figure imgf000042_0003
50 % yield
Figure imgf000042_0004
Figure imgf000042_0005
The following compounds were prepared according to the general processes described above. Those skilled in the art are familiar with the starting materials that are needed to obtain said compounds.
Example 1 : 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H- pyrazole-3-carboxylic acid cycloheptylamide
Figure imgf000043_0001
IH NMR (300 MHz, DMSCW6) δ ppm 1.34 - 1.65 (m, 12 H) 1.75 (s., 3 H) 3.30 (d, 7=2.20 Hz, 2 H) 3.84 (m, 1 H) 6.79 (d, 7=8.79 Hz, 1 H) 7.26 (dd, 7=8.64, 2.34 Hz, 1 H) 7.40 (s, 4 H) 7.54 (d, 7=2.49 Hz, 1 H) 7.87 (d, 7=8.20 Hz, 1 H)
MS (M+H, APCI)+: 478
Example 2: 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1H- pyrazole-3-carboxylic acid azepan-1-ylamide; hydrochloride
Figure imgf000044_0001
IH NMR (300 MHz, DMSO-</6) δ ppm 1.59 (br. s., 8 H) 1.78 (s., 3 H) 3.38 (m, 6 H) 6.77 (d, 7=8.79 Hz, 1 H) 7.29 (dd, 7=8.64, 2.49 Hz, 1 H) 7.43 (s, 4 H) 7.60 (d, 7=2.34 Hz, 1 H) 11.01(br. s., 1 H)
MS (M+H, APCI)+: 479
Example 3: 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1H- pyrazole-3-carboxylic acid piperidin-1-ylamide; hydrochloride
Figure imgf000045_0001
IH NMR (300 MHz, DMSO-^6) δ ppm 1.42 (br. s., 2 H) 1.59 (s, 3 H) 1.73 (br. s., 4 H) 3.15 (br. s., 4 H) 3.37 (s, 2 H) 6.78 (d, 7=8.64 Hz, 1 H) 7.29 (dd, 7=8.64, 2.34 Hz, 1 H) 7.43 (s, 4 H) 7.59 (d, 7=2.49 Hz, 1 H) 10.58 (br. s., I H)
MS (M+H, APCI)+: 465
Example 4: 5-(4-Chlorophenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H- pyrazole-3-carboxylic acid
Figure imgf000046_0001
IH NMR (300 MHz, CHLOROFORM-*/) δ ppm 1.69 (s, 3 H) 3.41 (d, 7=3.81 Hz, 2 H) 6.46 (d, 7=8.64 Hz, 1 H) 6.97 (dd, 7=8.64, 2.34 Hz, 1 H) 7.30 - 7.42 (m, 2 H) 7.35 (d, 7=4.98 Hz, 3 H)
MS (M+H, APCI)+: 383
Example 5: 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1H- pyrazole-3-carboxylic acid ethyl ester
Figure imgf000046_0002
IH NMR (300 MHz, CHLOROFORM-^ δ ppm 1.37 (t, 7=7.03 Hz, 3 H) 1.66 (s, 3 H) 3.39 (d, 7=2.78 Hz, 2 H) 4.35 (q, ./=7.03 Hz, 2 H) 6.49 (d, 7=8.64 Hz, 1 H) 6.95 (dd, 7=8.64, 2.34 Hz, 1 H) 7.30 - 7.39 (m, 5 H)
MS (M+H, APCI)+: 411
Experimental procedures
The chemical examples (above) were prepared following in general the following procedure:
a)
Figure imgf000047_0001
70-80% yield
Figure imgf000047_0002
To a stirred solution of 2,4-dichloroaniline (6.00 g, 37 mmol) and concentrated hydrochloric acid (9 ml) in ice (9 ml) a solution of NaNO2 (2.76 g, 40 mmol) in water (5 ml) is slowly added and the mixture is stirred for 1 h at 0-5 0C. Then, this solution is added over a cold mixture of NaOAc (9.87 g, 120 mmol), ethanol (156 ml) and ethyl-2-chloro-3-oxobutanoate (6.09 g, 37 mmol) and let stirring for 1 hour until the formed precipitate is collected by filtration, washed with ethanol and dichloromethane and dried in vacuo to give the yellow solid ethyl 2-chloro-2- (2-(2,4-diclhorophenyl)hydrazono)acetate (8.32 g, 78 % yield), which is used in the next step without any further purification.
b)
Figure imgf000047_0003
50 % yield Then, triethylamine (3.41 g, 33.7 mmol, 2.8 eq) is added to a solution of ethyl 2-chloro-2-(2- (2,4-diclhorophenyl)hydrazono)acetate (3.56 g, 12 mmol, 1 eq) and 4-chloro-α- methylstyrene (5.52 g, 36.1 mmol, 3 eq) in toluene (22 ml), and the mixture is stirred at reflux temperature for 1 hour. The formed precipitate is removed by filtration after cooling to room temperature. The filtrate is concentrated and purified using a Combiflah system from Isco, eluting with cyclohexane and ethyl acetate (in a gradient program until 10% AcOEt), to obtain ethyl 5-(4-chlorophenyl)-1 -(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3- carboxylate (2.47 g, 50 % yield).
Ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1H-pyrazo!e-3- carboxylate:
1 H NMR (300 MHz, CHLOROFORM-cQ δ ppm 1.37 (t, J=7.03 Hz, 3 H) 1.66 (s, 3 H) 3.39 (d, J=2.78 Hz, 2 H) 4.35 (q, J=7.03 Hz, 2 H) 6.49 (d, J=8.64 Hz, 1 H) 6.95 (dd, J=8.64, 2.34 Hz, 1 H) 7.30 - 7.39 (m, 5 H)
MS (M+H, APCI)+: 411
c)
Figure imgf000048_0001
85 % yield
Ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3- carboxylate (1.97 g, 4.8 mmol) are hydrolyzed in the presence of aqueous 2 M NaOH (384 mg, 9.6 mmol) and tetrahydrofuran (35 ml) for 4 hours. Then, tetrahydrofuran is partially removed by evaporation, 1 M HCI is added until pH is below 3 and the aqueous mixture is extracted with ethyl acetate, dried over Na2SO4, filtered and concentrated in vacuo to yield a white solid identified as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H- pyrazole-3-carboxylic acid (1.55 g, 85 % yield).
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1H-pyrazole-3- carboxylic acid: 1 H NMR (300 MHz, CHLOROFORM-cO δ ppm 1.69 (s, 3 H) 3.41 (d, J=3.81 Hz1 2 H) 6.46 (d, J=8.64 Hz, 1 H) 6.97 (dd, J=8.64, 2.34 Hz, 1 H) 7.30 - 7.42 (m, 2 H) 7.35 (d, J=4.98 Hz, 3 H)
d)
Figure imgf000049_0001
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carboxylic acid (1.52 g, 3.96 mmols) obtained according to the step above was dissolved in 10 mL of dry toluene and thionyl chloride (0.56 g, 4.75 mmols) was added. The mixture is heated to 80 0C for 2.5 hours. The solvent is removed under reduced pressure and the resulting crude residue is used without any further purification.
Under nitrogen atmosphere H2N-R compound (amine or hydrazine) (1.52 mmoles) and /V,Λ/-diisopropylethylamine (DIPEA) (0.522 mL, 3.05 mmol) were dissolved in methylene chloride (10 mL). The resulting mixture was ice-cooled down to 00C and Oa solution of 5-(4- chlorophenyl)-1 -(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carbonyl chloride (0.51O g, 1.27 mmoles), obtained in the former step, in methylene chloride (2 mL) was added dropwise. The resulting reaction mixture was stirred at room temperature (approximately 25 0C) overnight. Afterwards the reaction mixture was washed with water, followed by a saturated aqueous solution of sodium bicarbonate, then again with water, dried over sodium sulfate, filtered and evaporated to dryness in a rotavapor. The resulting crude was crystallized from ethanol, ethyl acetate or acetone. The crystallized solid was removed via filtration and the mother liquors were concentrated to yield a second fraction of crystallized product. The two fractions were combined to give the desired product (yield range: 70-90 %). Sometimes, a solution of 2 N HCI in diethyl ether or 2.8 N in ethanol is added to form the hydrochloride, which is collected by filtration. Pharmacological Data:
Pharmacological Methods
I. In-vitro determination of inhibition of ACAT (Acyl CoA-C holesterol Acyltransferase)
The in-vitro determination of the inhibition of the enzyme ACAT by the compounds of the invention is carried out in principle as described in the publication of Largis EE, Wang CH, DeVries VG and Schaffer SA (1989), "A Novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption", J. Lipid Res. 30, 681-689, (1989), whereby hepatic microsomes are used. The radio-substrate used is [14C]-Palmitoyl CoA. The respective parts of the description are hereby incorporated by reference and forms part of the present disclosure.
Briefly hepatic microsomes were prepared from the Wistar rats. Enzyme inhibition experiments were performed in presence of 18 μM [14C]-Palmitoyl CoA as substrate. The vehicle used was 1% DMSO. Compounds to be tested were present at various concentrations and the incubation buffer used was 0.2 M Phosphate buffer, pH 7.4 at 25°C. After a 15 minutes preincubation period at 370C an incubation period of 10 minutes at 37°C followed. Quantification of [14C]Cholesterol ester was done by column chromatography. The reference compound used was Lovastatin, which has a reported IC50 of 29 μM.
Results:
The inhibition of the enzyme ACAT by the inventive substituted pyrazoline compounds was determined as described above. Some of the inhibition data and IC50-values obtained in various experiments are given in the tables below:
Figure imgf000050_0001
Figure imgf000051_0001
and
Figure imgf000051_0002

Claims

Claims:
1. Substituted pyrazoline compound of general formula I,
Figure imgf000052_0001
wherein
Z is Ci-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z' is selected from hydrogen; C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an optionally at least monsubstituted mono- or polycyclic ring-system;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear d-3-alkyl group, while R9 is representing an optionally at least monsubstituted mono- or polycyclic ring-system; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof; with the following provisos: if Z' is H, Y is p-toluol and R10 is -OCH3, then X may not be monosubstituted cyclohexene; and if Z' is H, Y is 2,4-dichlorophenyl, X is unsubstituted phenyl and R10 is -OC2H5, then Z may not be CH3; and if Z' is H, Y is 2,4-dibromophenyl, X is unsubstituted phenyl and R10 is -OC2H5, then Z may not be CH3; and if Z' is H, Y is 2-chloro-4-trifluoromethyl-phenyl, X is unsubstituted phenyl and R10 is -
OC2H5, then Z may not be CH3; and if Z' is H, Y is 2,4-dichlorophenyl, X is 4-Chloro-phenyl and R10 is -OC2H5, then Z may not be CH3; and if Z' is H, Y is 4-chloro-2-trifluoromethyl-phenyl, X is unsubstituted phenyl and R10 is -
OC2H5, then Z may not be CH3; and if Z' is H, and X and Y are phenyl and R10 is NR8R9, R9 may not be phenyl.
2. Substituted pyrazoline compound according to claim 1 according to general formula I, wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z' is selected from hydrogen; C^-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear Ci-3-alkyl or branched or linear Ci-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear d-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H1 F, Cl, Br, I, OH, SH, C^alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H1 F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F1 OCF3, a keto-group, NO2 or NH2;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof. Substituted pyrazoline compound according to any of claims 1 or 2 according to general formula I1 wherein
Z is d-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
Z' is selected from hydrogen; d-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
X and Y independently represent an phenyl, thienyl, naphtyl or pyridyl, which groups are unsubstituted or may be substituted with 1 , 2 or 3 substituents W, which can be the same or different, selected from the group branched or linear C1-3-alkyl or branched or linear Ci-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear Ci-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F1 Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F1 Cl1 Br1 I, OH, SH1 C1-4alkyl, C1^aIkOXy1 CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
4. Substituted pyrazoline compound according to any of claims 1 to 3, wherein
Z is CH3 or C2H5; and/or
Z' is hydrogen; and/or
X and Y independently represent phenyl or thienyl; preferably Y representing phenyl, while X represents phenyl or thienyl; more preferably X and Y representing phenyl; and/or
R10 represents OR8' with
R8 representing a hydrogen atom or a branched or linear
Figure imgf000056_0001
group, preferably hydrogen, CH3 or C2H5;
or
R10 represents NR8R9, with
R8 representing a hydrogen atom or a branched or linear Ci-3-alkyl group, preferably hydrogen; and
R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical; or R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical.
5. Substituted pyrazoline compound according to any of claims 1 to 4 characterized in that the compound is a compound of general formula Il
Figure imgf000057_0001
wherein
Z is d-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R10 represents OR8' or NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, or
either
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F1 Cl1 Br, I, OH1 SH, C1-4alkyl, C1-4alkoxy. CF3, CHF2, CH2F1 OCF3, a keto-group, NO2 or NH2;
or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I1 OH, SH, C1-4alkyl, C^alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear Ci-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH1 trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-20-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
6. Substituted pyrazoline compound according to claim 5, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH1 SH, F, Cl, Br, I CF3, CHF2, CH2F1 OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH1 OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R10 represents OR8' with
R8 representing a hydrogen atom or a branched or linear C1-4-alkyl group, preferably hydrogen, CH3 or C2H5;
or
R10 represents NR8R9, with
R8 representing a hydrogen atom or a branched or linear C1-3-alkyl group, preferably hydrogen; and
R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical; or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical.
7. Substituted pyrazoline compound according to any of claims 1 to 6, characterized in that the compound is a compound of general formula III
Figure imgf000059_0001
(III) wherein
Z is d-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear Ci-3-alkyl group, while R9 is representing an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH1 C^alkyl, C^alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
or
R8 and R9 together with the connecting Nitrogen atom are representing an optionally at least monsubstituted heterocyclyl radical; which group is unsubstituted or may be substituted with R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2;
R11, R12, R13 and R14 independently of one another represent:
H; branched or linear Ci-3-alkyl or branched or linear Ci-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-Ci-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
8. Substituted pyrazoline compound according to claim 7, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R8 represents a hydrogen atom;
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2.
Substituted pyrazoline compound according to any of claims 1 to 8 characterized in that the compound is a compound of general formula IV
Figure imgf000061_0001
(IV) wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H1 F1 Cl, Br, I, OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F1 OCF3, a keto-group, NO2 or NH2;
R11 and R12 independently of one another represent:
H; branched or linear Ci-3-alkyl or branched or linear Ci-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
10. Substituted pyrazoline compound according to claim 9, wherein
R11 and R12 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F, Cl, Br1 I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H, F, Cl. Br, I1 OH, SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2.
11. Substituted pyrazoline compound according to claim 9, wherein
R11 and R12 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH1 SH, F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably represent H, OH, OCH3, F, Cl1 Br1 1, CF3, CHF2 or OCF3; more preferably represent Br, Cl, OH, OCH3, or H; most preferably represent H; and/or
Z is CH3 or C2H5; preferably is CH3; and/or
R9 represents an aryl radical, cycloalkyl radical, or heterocyclyl radical, which groups are unsubstituted or may be substituted with; R5, R6 and R7, which can be the same or different, with R5, R6 and R7 being independently from one another selected from H1 F1 Cl1 Br, I1 OH1 SH, C1-4alkyl, C1-4alkoxy, CF3, CHF2, CH2F, OCF3, a keto-group, NO2 or NH2; preferably represents an unsubstituted aryl radical, cycloalkyl radical, or heterocyclyl radical.
12. Substituted pyrazoline compound according to claim 9, wherein
R11 and R12 independently of one another represent H1 CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH, F1 Cl, Br1 I CF3, CHF2, CH2F, OCF3, OCHF2; preferably represent H1 OH1 OCH3, F1 Cl1 Br1 11 CF3, CHF2 or OCF3; more preferably represent Br1 Cl1 OH, OCH3, or H; most preferably represent H; and
Z is CH3 or C2H5; preferably is CH3; and R9 represents
a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2)- (CH2J-(CH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH1 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n- pentyl, 2-pentyl and n-hexyl;
a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2HCH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
or a radical selected from the group consisting of
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000065_0003
which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals; preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or of the group consisting of
Figure imgf000067_0001
Figure imgf000067_0002
Figure imgf000067_0003
Figure imgf000067_0004
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals; more preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
Figure imgf000068_0001
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals.
13. Substituted pyrazoline compound according to any of claims 1 to 12, wherein
R9 represents
a radical selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl and bicyclo[2.2.1]heptyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2)- (CH2HCH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of - OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2-butyl, tert-butyl, n- pentyl, 2-pentyl and n-hexyl;
a radical selected from the group consisting of phenyl, naphthyl, pyridinyl, furyl (furanyl), thienyl (thiophenyl) and triazolyl, which may be bonded via a -(CH2)-, -(CH2HCH2)-, -(CH2)-(CH2)-(CH2)- or -CH=CH-group and/or may optionally be substituted with 1 , 2, 3, 4 or 5 substituent(s) independently selected from the group consisting of -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 2- butyl, tert-butyl, n-pentyl, 2-pentyl, n-hexyl, F, Cl and Br;
or a radical selected from the group consisting of
Figure imgf000069_0001
Figure imgf000069_0002
Figure imgf000069_0003
Figure imgf000069_0004
which is in each case bonded to the pyrazoline compound of general formula I in any position of the cyclic part of the aforementioned radicals including the NH-groups, preferably said radicals are bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals;
more preferably R9 represents a radical selected from the group consisting of phenyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl or from the group of
Figure imgf000070_0001
which is in each case bonded to the pyrazoline compound of general formula I at the nitrogen atom of the cyclic part of the aforementioned radicals.
14. Compound according to any of claims 1 to 13 selected from the group consisting of:
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid piperidin-1-ylamide; hydrochloride;
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid azepan-1 -ylamide; hydrochloride;
• 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid cycloheptylamide;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
15. Substituted pyrazoline compound according to any of claims 1 to 6 characterized in that the compound is a compound of general formula V
Figure imgf000071_0001
(V)
wherein
Z is d-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear C^-alkyl group;
R , R 1 R and R independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear d-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH, trifluoromethyl, CHF2, CH2F1 OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
16. Substituted pyrazoline compound according to claim 15, wherein
R11, R12, R13 and R14 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH1 F, Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably R11, R12, R13 and R14 independently of one another represent H, OH, OCH3, F, Cl, Br, I, CF3, CHF2 or OCF3; and/or
Z is CH3 or C2H5; and/or
R8 represents a hydrogen atom, CH3 or C2H5.
17. Substituted pyrazoline compound according to claim 15, characterized in that the compound is a compound of general formula Vl
Figure imgf000072_0001
(Vl)
wherein
Z is C1-4-Alkyl, substituted or unsubstituted, branched or linear, saturated or unsaturated;
R8 represents a hydrogen atom or a branched or linear d-4-alkyl group; R11 and R12 independently of one another represent:
H; branched or linear C1-3-alkyl or branched or linear C1-3-alkoxy, phenyl, hydroxy, chloro, bromo, fluoro, iodo, SH1 trifluoromethyl, CHF2, CH2F, OCHF2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, with P denominating a prodrug group consisting of aryl, C8-2o-alkyl, heteroaryl, C(O)-aryl, C(O)-heteroaryl, C(O)-C1-20-alkyl;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.
18. Substituted pyrazoline compound according to claim 17, wherein
R11 and R12 independently of one another represent H, CH3, C2H5, C3H7, OCH3, OC2H5, OH, SH1 F1 Cl, Br, I CF3, CHF2, CH2F, OCF3, OCHF2; preferably represent H, OH, OCH3, F1 Cl, Br, I1 CF3, CHF2 Or OCF3; more preferably represent Br, Cl1 OH, OCH3, or H; most preferably represent H; and/or
Z is CH3 or C2H5; preferably is CH3; and/or
R8 is hydrogen, CH3 or C2H5; preferably is hydrogen or C2H5.
19. Compound according to any of claims 1 to 6 and 15 to 18 selected from the group consisting of:
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid;
• 5-(4-Chloro-phenyl)-1 -(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole- 3-carboxylic acid ethyl ester;
optionally in the form of its racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
20. Medicament comprising at least one substituted pyrazoline compound of general formula I according to claims 1 to 19, and optionally one or more pharmaceutically acceptable excipients.
21. Use of at least one substituted pyrazoline compound according to one or more of claims 1 to 19 and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of dyslipidaemia; diabetes Type II, Metabolic Syndrome or obesity; especially dyslipidaemia.
PCT/EP2008/000343 2007-01-17 2008-01-17 Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments WO2008087030A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08707108A EP2114892A1 (en) 2007-01-17 2008-01-17 Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments
US12/523,451 US20100069364A1 (en) 2007-01-17 2008-01-17 Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07000947A EP1947088A1 (en) 2007-01-17 2007-01-17 Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments
EP07000947.7 2007-01-17
EP07384013A EP1950203A1 (en) 2007-01-24 2007-01-24 Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments
EP07384013.4 2007-01-24

Publications (1)

Publication Number Publication Date
WO2008087030A1 true WO2008087030A1 (en) 2008-07-24

Family

ID=39402640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/000343 WO2008087030A1 (en) 2007-01-17 2008-01-17 Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments

Country Status (3)

Country Link
US (1) US20100069364A1 (en)
EP (1) EP2114892A1 (en)
WO (1) WO2008087030A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005046A2 (en) * 1987-01-05 1988-07-14 E.I. Du Pont De Nemours And Company Insecticidal pyrazolines
EP0322126A1 (en) * 1987-11-30 1989-06-28 E.I. Du Pont De Nemours And Company Heterocyclic pyrazoline carboxanilides
WO1991007874A1 (en) * 1989-11-30 1991-06-13 Hoechst Aktiengesellschaft Pyrazolines for the protection of crops against herbicides
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5700758A (en) * 1989-11-30 1997-12-23 Hoechst Aktiengesellschaft Pyrazolines for protecting crop plants against herbicides
US7745476B2 (en) * 2004-01-30 2010-06-29 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005046A2 (en) * 1987-01-05 1988-07-14 E.I. Du Pont De Nemours And Company Insecticidal pyrazolines
EP0322126A1 (en) * 1987-11-30 1989-06-28 E.I. Du Pont De Nemours And Company Heterocyclic pyrazoline carboxanilides
WO1991007874A1 (en) * 1989-11-30 1991-06-13 Hoechst Aktiengesellschaft Pyrazolines for the protection of crops against herbicides
WO2005077909A1 (en) * 2004-02-17 2005-08-25 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE BENASSUTI L ET AL: "Oxygenated monoterpenes as dipolarophiles for nitrilimine cycloadditions", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 21, 17 May 2004 (2004-05-17), pages 4627 - 4633, XP004506200, ISSN: 0040-4020 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Also Published As

Publication number Publication date
EP2114892A1 (en) 2009-11-11
US20100069364A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
JP4633928B2 (en) Pyrazoline derivatives, their preparation and pharmaceutical applications
US8106085B2 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2005077909A1 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
EP1757587A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP2114892A1 (en) Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments
WO2008087029A1 (en) Substituted pyrazoline compounds with acat inhibition activity
EP1947088A1 (en) Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments
EP1950203A1 (en) Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments
EP1947087A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
EP1950202A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
EP1637522A1 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
WO2007009706A2 (en) Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
US7998996B2 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
EP1746090A1 (en) Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
ES2325569B1 (en) CICLOALCANOSUSTITUID PIRAZOLINE COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS
EP1849784A1 (en) Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1849783A1 (en) Octahydropentalene-substituted pyrazoline compounds, their preparation and use as medicaments
EP1849776A1 (en) Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009702A2 (en) Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743889A1 (en) Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
MXPA00011839A (en) Pyrazoline derivatives, their preparation and application as medicaments
MXPA06009335A (en) Substituted pyrazoline compounds for reducing triglycerides in blood

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08707108

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008707108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12523451

Country of ref document: US